Management of diabetic dyslipidemia: An update

查看全文 作　　者：Ishwarlal [1]Jialal;Gurdeep [2]Singh

机构地区：[1]California North-state University College of Medicine, VA Medical Center;[2]Lady of Lourdes Memorial Hospital

出　　处：《World Journal of Diabetes》索引2019年第10卷第5期,共11页

摘　　要：Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride level, decreased high-density lipoprotein-cholesterol levels and increase in small dense low-density lipoprotein(LDL) particles. It is extremely common in type 2 diabetes(T2DM) affecting around 70 % of patients.Diabetic is a significant risk factor for atherosclerotic cardiovascular disease(ASCVD) which is the most common cause of death in the United States and LDL-cholesterol is the number 1 predictor of ASCVD events in T2DM. The purpose of this review is to discuss the pathophysiology and treatment of diabetic dyslipidemia. In this review, we have discussed both nonpharmacological and pharmacological treatment modalities including major treatment trials which have impacted the cardiovascular outcomes in patients with diabetes. Statin therapy is the mainstay of treatment to reduce ASCVD by decreasing LDL-C by 30%-49% or at least 50% depending on risk level. Attractive adjunctive therapies include Ezetimibe which is more cost effective and PCSK9 inhibitors which display potent LDL-cholesterol lowering and ASCVD event reduction. For severe hypertriglyceridemia, to avert the risk of pancreatitis, both fish oil and fenofibrate in concert with diet is the best strategy. 关键词：Diabetes DYSLIPIDEMIA STATINS ATHEROSCLEROSIS EZETIMIBE PCSK9

相关文献

参考文献（59）
引证文献（9）
耦合文献（0）

参考文献(59)

引证文献(9)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Management of diabetic dyslipidemia: An update

参考文献(59)

引证文献(9)

用户提示